Evidence map›Paper›PMID 35407131›Full record

ReviewFoods (Basel, Switzerland)2022

Nutraceuticals and Diet Supplements in Crohn's Disease: A General Overview of the Most Promising Approaches in the Clinic.

Barbara De Conno, Marcella Pesce, Martina Chiurazzi, Marta Andreozzi, Sara Rurgo, Chiara Corpetti, Luisa Seguella, Alessandro Del Re, Irene Palenca, Giuseppe Esposito and 1 more

Open access · goldAbstract readReview
In one paragraph

Review in Foods (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Next-Generation Probiotics for Inflammatory Bowel Disease.International journal of molecular sciences · 2022
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Barbara De ConnoDepartment of Clinical Medicine and Surgery, University of Naples "Federico II", 80131 Naples, Italy.ORCID 0000-0001-6205-8513
Marcella PesceDepartment of Clinical Medicine and Surgery, University of Naples "Federico II", 80131 Naples, Italy.ORCID 0000-0001-5996-4259
Martina ChiurazziDepartment of Clinical Medicine and Surgery, University of Naples "Federico II", 80131 Naples, Italy.
Marta AndreozziDepartment of Clinical Medicine and Surgery, University of Naples "Federico II", 80131 Naples, Italy.
Sara RurgoDepartment of Clinical Medicine and Surgery, University of Naples "Federico II", 80131 Naples, Italy.
Chiara CorpettiDepartment of Physiology and Pharmacology "V. Erspamer", "Sapienza" University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.
Luisa SeguellaDepartment of Physiology and Pharmacology "V. Erspamer", "Sapienza" University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.
Alessandro Del ReDepartment of Physiology and Pharmacology "V. Erspamer", "Sapienza" University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.
Irene PalencaDepartment of Physiology and Pharmacology "V. Erspamer", "Sapienza" University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.ORCID 0000-0001-5019-653X
Giuseppe EspositoDepartment of Physiology and Pharmacology "V. Erspamer", "Sapienza" University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.ORCID 0000-0001-8080-8218
Giovanni SarnelliDepartment of Clinical Medicine and Surgery, University of Naples "Federico II", 80131 Naples, Italy.ORCID 0000-0002-1467-1134
University of Naples Federico II · ITSapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Crohn's disease (CD) is a chronic inflammatory gastrointestinal disorder requiring lifelong medications. The currently approved drugs for CD are associated with relevant side effects and several studies suggest an increased use of nutraceuticals among CD patients, seeking for what is perceived as a more "natural" approach in controlling this highly morbid condition. Nutraceuticals are foods or foods' components with beneficial health properties that could aid in CD treatment for their anti-inflammatory, analgesic and immunoregulatory activities that come along with safety, high tolerability, easy availability and affordability. Depending on their biological effect, nutraceuticals' support could be employed in different subsets of CD patients, both those with active disease, as adjunctive immunomodulatory therapies, and/or in quiescent disease to provide symptomatic relief in patients with residual functional symptoms. Despite the increasing interest of the general public, both limited research and lack of education from healthcare professionals regarding their real clinical effectiveness account for the increasing number of patients turning to unconventional sources. Professionals should recognize their widespread use and the evidence base for or against their efficacy to properly counsel IBD patients. Overall, nutraceuticals appear to be safe complements to conventional therapies; nonetheless, little quality evidence supports a positive impact on underlying inflammatory activity.

Indexed as

Crohn’s diseaseinflammatory bowel diseaseslactoferrinnutraceutical compoundspalmytoilethanolamide (PEA)phytotherapicsprobiotics

Identifiers

PMID35407131
PMCPMC8998137
OpenAlexW4223494208

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.